ArticleESMO open2026

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer: results from the TROPION-Breast01 China cohort.

S Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.